Animal Or Plant Cell Patents (Class 424/93.7)
-
Patent number: 10017738Abstract: The present invention is directed to purified preparations of dermal mesenchymal stem cells that are characterized by the cell surface expression of the ABCB5 P-glycoprotein. The cells may be used for any purpose that mesenchymal stem cells from other course are used. For instance they may be administered to treat an organ transplant recipient to improve allograft survival or as a treatment to patients with autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.Type: GrantFiled: March 15, 2013Date of Patent: July 10, 2018Assignee: Children's Medical Center CorporationInventor: Markus H. Frank
-
Patent number: 10016460Abstract: The present invention relates generally to a method of producing a population of cells and materials for use therewith. More particularly, the present invention is directed to a method of generating the growth of a population of blood-derived cells and materials for use therewith. The method of the present invention facilitates cell growth by virtue of the migration of blood-derived cells from the vasculature of a vascularized receptacle to the acellular tissue support matrix of said receptacle. These findings have now facilitated the design of means for reliably and efficiently deriving cellular populations from blood-derived cells, such as the generation of bone marrow cells including haemopoietic stem cells and mesenchymal stem cells, for use in a wide variety of clinical and research settings.Type: GrantFiled: November 26, 2010Date of Patent: July 10, 2018Inventors: Stephen Anthony Livesey, Kathy Traianedes
-
Patent number: 10016486Abstract: Methods and compositions using a combination of adenosine monophosphate protein kinase (AMPK) activators for treating pain such as post-surgical pain or development of chronic pain. The two or more AMPK activators work synergistically and may be administered in individually sub-efficacious doses. The AMPK activators may have different mechanisms of AMPK activation. The AMPK activators may be administered systemically and/or topically in, for example, as a gel, ointment, cream, lotion, suspension, liquid, or transdermal patch.Type: GrantFiled: December 1, 2015Date of Patent: July 10, 2018Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONAInventors: Dong-Chul Pyun, Theodore J. Price, Gregory D. Dussor, Dipti Tillu, Bo Lian
-
Patent number: 10017741Abstract: The disclosure provides a method of culturing cells of the mesenchymal cell lineage, said method comprising contacting the cells with a culture media comprising a CSF1R kinase inhibitor. The disclosure also provides a method of culturing cells from bone marrow and/or compact bone to enrich the cells with cells of the mesenchymal cell lineage comprising contacting the cells with a culture media comprising a CSF1R kinase inhibitor. Cell culture media comprising a CSF1R kinase inhibitor and useful for culturing cells of the mesenchymal cell lineage and/or enriching cells of the mesenchymal cell lineage is also provided.Type: GrantFiled: March 12, 2014Date of Patent: July 10, 2018Assignee: STEMCELL TECHNOLOGIES INC.Inventors: Brenton John Short, Christopher Duronio
-
Patent number: 10000746Abstract: Disclosed herein are compositions for inactivating the human TCR-alpha gene comprising engineered LAGLIDADG homing endonucleases (LHEs) and their derivatives, particularly derived from members of the \-Onul subfamily of LHEs. Polynucleotides encoding such endonucleases, vectors comprising said polynucleotides, cells comprising or having been treated with such endonucleases, and therapeutic compositions deriving therefore are also provided.Type: GrantFiled: May 28, 2014Date of Patent: June 19, 2018Assignees: CELLECTIS, PRECISION GENOME ENGINEERING, INC.Inventors: Jordan Jarjour, Alexander Astrakhan
-
Patent number: 9994814Abstract: A method comprising obtaining a donor composition from a donor subject wherein the donor composition comprises a plurality of adult stem cell types; obtaining a receiver composition from a receiver subject wherein the receiver composition comprises a plurality of adult stem cell types; and co-culturing the donor composition and receiver composition wherein co-culturing comprises contacting the receiver composition a cell-free portion of the donor composition to produce a restored composition. Pharmaceutical compositions comprising a restored composition.Type: GrantFiled: April 9, 2014Date of Patent: June 12, 2018Assignee: Advanced Regen Medical Technologies, LLCInventor: Vincent C. Giampapa
-
Patent number: 9993505Abstract: Methods of generating an innervated muscle structures are disclosed as well as bioengineered structures for tissue repair or regeneration. The methods can include the steps of obtaining populations of smooth muscle cells and neuronal progenitor cells and then seeding the cells together onto a matrix material, followed by culturing the seeded cells to form an innervated smooth muscle cell construct of directionally oriented smooth muscle cells. In one embodiment, the neuronal progenitor cells can be seeded first as neurospheres in a biocompatible solution, e.g., a collagen/laminin solution, and allowed to gel. Next, a second suspension of smooth muscle cells can be deposited as separate layer. Multiple layer structures of alternating muscle or neuron composition can also be formed in this manner. Differentiation of the neuronal progenitor cells can be induced by exposure to a differentiation medium, such as Neurobasal A medium and/or exposure to a differentiating agent, such as B-27 supplement.Type: GrantFiled: January 31, 2013Date of Patent: June 12, 2018Assignee: Wake Forest University Health SciencesInventor: Khalil Bitar
-
Patent number: 9988685Abstract: Methods and kits for diagnosing, prognosticating risk of, and selecting and/or administering a therapy for breast cancer based upon detection of methylated glucocorticoid receptor gene or measurement of glucocorticoid receptor and BRCA1 gene expression levels are provided.Type: GrantFiled: March 11, 2014Date of Patent: June 5, 2018Assignee: QUEEN'S UNIVERSITY AT KINGSTONInventors: Christopher Robert Mueller, Kirsten A. Nesset
-
Patent number: 9988603Abstract: The present invention provides a method of generating megakaryocytes and platelets. In various embodiments, method involves the use of human embryonic stem cell derived hemangioblasts for differentiation into megakaryocytes and platelets under serum and stromal-free condition. In this system, hESCs are directed towards megakaryocytes through embryoid body formation and hemangioblast differentiation. Further provided is a method of treating a subject in need of platelet transfusion.Type: GrantFiled: December 3, 2010Date of Patent: June 5, 2018Assignee: Stem Cell & Regenerative Medicine InternationalInventors: Feng Li, Shi-Jiang Lu
-
Patent number: 9987310Abstract: Provided are pharmaceutical compositions that include a pharmaceutically acceptable carrier and isolated post-natal cardiac progenitor cells (CPCs) and/or progeny cells thereof that are SSEA3-positive and c-kit-negative. Also provided are methods for preparing cells capable of repairing damaged myocardium, methods for isolating populations of SSEA3-positive/c-kit-negative CPCs from cardiac tissue samples, methods for preparing an isolated cell population enriched in post-natal SSEA3-positive/c-kit-negative CPCs, therapeutic methods for using the presently disclosed cells and populations of cells to treat subjects in need thereof, and cell cultures that contain the presently disclosed cells and populations of cells.Type: GrantFiled: November 25, 2014Date of Patent: June 5, 2018Assignee: University of Louisville Research Foundation, Inc.Inventors: Matthew C. L. Keith, Marcin Wysoczynski, Roberto Bolli
-
Patent number: 9982237Abstract: The invention provides a composition and a method for inducing pluripotency in non-pluripotent eukaryotic cells. The composition comprises chemical inducers of pluripotency (CIPs) including glycogen synthase kinase (GSK) inhibitors, TGFp receptor inhibitors, cyclic AMP agonists, S-adenosylhomocysteine hydrolase (SAH) inhibitors, and optionally an agent that promotes histone acetylation. The method comprises contacting a cell with the CIPs for a sufficient period of time to reprogram the cell into a pluripotent stem cell.Type: GrantFiled: July 10, 2014Date of Patent: May 29, 2018Assignee: Hong Guan, Ltd.Inventors: Hongkui Deng, Yang Zhao, Pingping Hou, Yanqin Li, Xu Zhang, Chun Liu, Jingyang Guan, Honggang Li
-
Patent number: 9982238Abstract: A method for producing a regenerative organ germ for transplantation includes using regenerative organ germ for transplantation ensuring continuity with a recipient after transplantation and facilitating transplantation procedures. A method for producing a regenerative organ germ provided with a guide for transplantation includes preparing a regenerative organ germ by closely contacting a first cell mass, which substantially consists of mesenchymal cells, and a second cell mass, which substantially consists of epithelial cells, culturing these cell masses within a support, and inserting the guide into the regenerative organ germ.Type: GrantFiled: July 7, 2011Date of Patent: May 29, 2018Assignee: Organ Technologies, Inc.Inventors: Koh-ei Toyoshima, Takashi Tsuji
-
Patent number: 9980984Abstract: The present disclosure provides an inventive method of treating inflammation that is associated with osteoarthritis of the knee joint by injecting mesenchymal stem cells into the symptomatic knee. In one aspect, the mesenchymal stem cells are obtained autogenously. In another aspect, the mesenchymal stem cells are injected below the degenerated medial tibial plateau of the knee joint, resulting in reduction of the inflammation and alleviation of the symptoms of the osteoarthritis.Type: GrantFiled: October 13, 2016Date of Patent: May 29, 2018Inventor: Kenneth Allen Pettine
-
Patent number: 9977012Abstract: A method for cryopreservation of adherent cells attached to a substrate and a method for identifying one or more extracellular matrix (ECM) components and/or matricellular proteins that improves viability and retention of the cryopreserved cells on the substrate. The method for cryopreservation includes treating a substrate with at least one ECM component and/or adding at least one matricellular protein to the substrate or cell culture media, plating the cells on the treated substrate, and cryopreserving the cells. One or more ECM components and/or matricellular proteins that improves cell viability and retention can be identified by evaluating the cells that have been thawed from the cryopreservation temperature to determine cell viability and retention.Type: GrantFiled: October 24, 2014Date of Patent: May 22, 2018Assignee: LIFELINE SCIENTIFIC, INC.Inventors: Kelvin G. M. Brockbank, Lia Campbell
-
Patent number: 9974840Abstract: The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.Type: GrantFiled: September 11, 2013Date of Patent: May 22, 2018Assignee: Celularity, Inc.Inventors: Mohit Bhatia, Chris Lugo, Qian Ye, James W. Edinger
-
Patent number: 9976123Abstract: The present invention provides methods for cellular seeding onto three-dimensional fibroblast constructs, three-dimensional fibroblast constructs seeded with muscle cells, and uses therefore.Type: GrantFiled: May 21, 2015Date of Patent: May 22, 2018Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRSInventors: Jordan Lancaster, Steve Goldman
-
Patent number: 9974814Abstract: A method to provide an inflated decellularized extracellular matrix of a mammalian organ or a vascularized portion thereof, or a mammalian vascularized tissue or a vascularized portion thereof, an inflated decellularized extracellular matrix of a mammalian organ or a vascularized portion thereof, or a mammalian vascularized tissue or a vascularized portion thereof, and uses thereof, are provided.Type: GrantFiled: March 24, 2016Date of Patent: May 22, 2018Assignee: Miromatrix Medical Inc.Inventors: Aleksandr Katane, Dominique Seetapun, Jeffrey Ross
-
Patent number: 9969976Abstract: A method for the preparation and/or generation of immunomodulatory cells which comprises contacting a mesenchymal stem cell (MSC) and/or fibroblast cell population with peripheral blood leukocytes for between about 2 hours and about 25 days is described herein.Type: GrantFiled: October 22, 2010Date of Patent: May 15, 2018Assignee: CELLERIX, S.A.Inventors: Dirk Buescher, Olga De La Rosa
-
Patent number: 9969974Abstract: The present invention provides methods for generating oligodendrocyte progenitor cells from pluripotent cells, as well as methods for sustaining these oligodendrocyte progenitor cells in relatively pure cultures for long periods of time. The present invention also provides methods for further differentiating these oligodendrocyte progenitor cells into various glial cells.Type: GrantFiled: November 23, 2015Date of Patent: May 15, 2018Assignee: Case Western Reserve UniversityInventors: Paul J. Tesar, Robert H. Miller, Fadi J. Najm
-
Patent number: 9962409Abstract: Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection, engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes.Type: GrantFiled: March 31, 2010Date of Patent: May 8, 2018Assignee: Vestion, Inc.Inventors: Joshua Hare, Konstantinos Chatzistergos
-
Patent number: 9956250Abstract: Provided are uses of allogeneic interstitial vessel-layer cells and allogeneic mesenchymal progenitor cells in the preparation of a pharmaceutical composition for preventing or treating osteoarthritis (OA). Also provided is a pharmaceutical composition containing the allogeneic interstitial vessel-layer cells and the allogeneic mesenchymal progenitor cells.Type: GrantFiled: January 28, 2014Date of Patent: May 1, 2018Assignees: Cellular Biomedicine Group (Shanghai) Ltd, Cellular Biomedicine Group (Wuxi) Ltd.Inventors: Wei Cao, Xiaoling Zeng, Mohammad Abdul Kaium, Yujie Zhou
-
Patent number: 9958433Abstract: A method and system of in vitro developmental toxicity testing comprising the steps of micropatterning an extracellular matrix; growing embryonic stem cells on the micropatterned extracellular matrix in the presence of mesoendodermal induction and testing for change of the geometrical mesoendoderm structure in the presence or absence of a test compound wherein (1) a decrease in mesoendodermal differentiation and/or (2) a change in morphology of the geometrical mesoendoderm structure in the presence of the test compound compared to cells in the absence of the test compound indicates that the test compound is a developmental toxic agent.Type: GrantFiled: September 30, 2013Date of Patent: May 1, 2018Assignee: Agency for Science, Technology and ResearchInventors: Hanry Yu, Yi-Chin Toh, Jiangwa Xing
-
Patent number: 9956317Abstract: Methods and kits for producing cellular fractions enriched in adipose derived stem cells. Methods are provided where adipose tissue obtained from liposuction is enzymatically treated using a solution containing collagenase and divalent cations prior to the application of traditional methods of stromal-vascular fraction isolation. The enzymatic solutions may contain collagenase types I and II to a final concentration of about 0.001 mg/ml to 0.010 mg/ml. The divalent cations may be present as calcium, magnesium, and zinc chloride. The final concentration of calcium, magnesium, and zinc may range from about 0.001 to 0.1 micromolar; about 0.005 to 0.5 micromolar; and about 0.0015 to 0.15 micromolar, respectively. The enzymatic solutions may be generated using a kit where the collagenase and divalent components are held in separate containers until just prior to use. The cellular fractions isolated in this manner may be used in autologous fat grafts in therapeutic applications.Type: GrantFiled: April 18, 2016Date of Patent: May 1, 2018Assignee: Antria, Inc.Inventor: Shahram Rahimian
-
Patent number: 9943354Abstract: Provided herein are methods, systems, and devices for increasing IL-10 expression, inhibiting inflammation, and treating inflammatory conditions using thermal ablation.Type: GrantFiled: March 8, 2013Date of Patent: April 17, 2018Assignee: Medtronic Ardian Luxembourg S.a.r.l.Inventors: Ayala Hezi-Yamit, Susan Thornton Edwards, Carol M. Sullivan
-
Patent number: 9919075Abstract: Certain embodiments described herein are directed to cohesive materials comprising treated, derivatized collagen molecules. In some embodiments, the cohesive material can function as a putty or defect filler that can be used in a tissue repair. Methods of using the cohesive materials are also described.Type: GrantFiled: March 19, 2015Date of Patent: March 20, 2018Assignee: Anexis, LLCInventors: Laurence J Berlowitz, Hans P. I. Claesson, Matthew Fullana, Gary E Wnek
-
Patent number: 9913865Abstract: Adult stem cells are reprogrammed to form pacemaker cells and Purkinje cells through the sequential activation of SHOX2>TBX5>HCN2. These Purkinje cells spontaneously surround and connect with the larger pacemaker cells, thus forming an induced sinoatrial body that produces funny current and can make cardiovascular tissues beat in a manner similar to a natural sinoatrial node.Type: GrantFiled: December 28, 2015Date of Patent: March 13, 2018Assignees: InGeneron Inc., Alliance of Cardiovascular ResearchInventors: Eckhard Alt, Tahereh Karimi
-
Patent number: 9914911Abstract: Disclosed herein are methods of producing induced pluripotent stem cells from chondrocytes, and further, methods of producing chondrocytes from said induced pluripotent stem cells. The invention further provides methods of regenerating cartilaginous tissue.Type: GrantFiled: October 29, 2013Date of Patent: March 13, 2018Assignee: SCRIPPS HEALTHInventors: Darryl D. d'Lima, Tsaiwei Olee, Clifford W. Colwell
-
Patent number: 9901548Abstract: This disclosure relates to compositions and methods for encapsulating biomaterials such as cells to prevent immune responses. In certain embodiments, the disclosure relates to capsules comprising a cell or cells gelled in alginate coated with a layer that prevents migration of immune molecules to the cell surface and an outer capsule layer comprising non-immunogenic material optionally containing immunosuppressive agents. In certain embodiments, the cells are capable of generating insulin that emanates from the capsule.Type: GrantFiled: March 14, 2012Date of Patent: February 27, 2018Assignee: EMORY UNIVERSITYInventors: Collin J. Weber, Susan A. Safley, Kereen S. Gordon, Nicholas E. Simpson
-
Patent number: 9901639Abstract: The present invention provides an isolated population of bone marrow-derived endothelial progenitor cells (EPCs) and uses thereof for the treatment of vascular diseases.Type: GrantFiled: February 16, 2016Date of Patent: February 27, 2018Assignee: Temple University—of the Commonwealth System of Higher EducationInventor: Hong Wang
-
Patent number: 9902933Abstract: The present invention provides a method of producing a cell sheet including the following steps (1) seeding and culturing retinal pigment epithelial cells on a collagen gel to form a cell sheet composed of the retinal pigment epithelial cells, and (2) degrading the collagen gel with collagenase to detach the cell sheet composed of the retinal pigment epithelial cells, and the like.Type: GrantFiled: February 24, 2012Date of Patent: February 27, 2018Assignee: RIKENInventors: Masayo Takahashi, Satoshi Okamoto, Hiroyuki Kamao
-
Patent number: 9902974Abstract: Methods and compositions comprising a fusion protein comprising a Cas protein and a functional domain in association with a single guide RNA targeted to an endogenous gene for genetic alteration of cells are provided.Type: GrantFiled: December 10, 2015Date of Patent: February 27, 2018Assignee: Sangamo Therapeutics, Inc.Inventors: Anthony Conway, Gregory J. Cost, Russell DeKelver, Edward J. Rebar, Andreas Reik, Fyodor Urnov, Jianbin Wang, H. Steve Zhang
-
Patent number: 9902935Abstract: The current invention concerns the use of PIP or S100A8 for the generation of regulatory T cells. The current invention provides a method of generating regulatory T cells by contacting immature DC with PIP or S100A8 to produce tolerogenic DC and further contacting naïve T cells to the tolerogenic DC to produce regulatory T cells. The invention also concerns PIP protein where immature DC contacted with PIP produce tolerogenic DC that induce conversion of naïve T-cells into regulatory T cells. The invention also concerns S100A8 protein where immature DC contacted with S100A8 produce tolerogenic DC that induce conversion of naïve T-cells into regulatory T cells. The invention also provides methods for identification of factors secreted by iNKT cells that induce conversion of immature DC into tolerogenic DC. The subject invention also concerns using regulatory T cells for treatment and/or management of cancer or the diseases of the immune system.Type: GrantFiled: January 24, 2014Date of Patent: February 27, 2018Assignee: UNIVERITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATEDInventors: Hyeong Woo Lee, Brian Samuel Wilson
-
Patent number: 9895399Abstract: The invention relates to methods and compositions for maintaining the pro-regenerative capacity of distal nerve segments following nerve injury.Type: GrantFiled: January 31, 2014Date of Patent: February 20, 2018Assignee: The Trustees of the University of PennsylvaniaInventors: Douglas H. Smith, Kacy D. Cullen, John A. Wolf
-
Patent number: 9896657Abstract: The present invention relates to a method of inducing differentiation of a stem cell into a corneal limbal stem cell, and a medium composition used therein. Further, the present invention relates to a pharmaceutical composition for treating corneal damage, including a corneal limbal stem cell differentiated using the above-described method as an active ingredient.Type: GrantFiled: August 11, 2015Date of Patent: February 20, 2018Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Choun-Ki Joo, Hyun Soo Lee
-
Patent number: 9890360Abstract: A method that includes bringing a nuclear reprogramming substance (DLX4 gene, OCT3/4 gene, and SOX2 gene) into contact with a cell and thereby producing iPS cells.Type: GrantFiled: August 28, 2014Date of Patent: February 13, 2018Assignees: GIFU UNIVERSITY, NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGYInventors: Kenichi Tezuka, Naritaka Tamaoki, Kazuki Iida, Tomoko Kawaguchi, Hitomi Aoki, Takahiro Kunisada, Toshiyuki Shibata, Naoki Goshima
-
Patent number: 9879278Abstract: The invention includes compositions and methods for the selective expression of a target gene in a subset of cells. In certain embodiments, the present invention includes a construct comprising a first nucleic acid sequence comprising an episomal maintenance element and a second nucleic acid sequence comprising a target gene wherein the expression of the episomal maintenance element is regulated by a constitutive promoter and the expression of the target gene is regulated by a non-constitutive promoter. The construct is able to maintain episomal state, no matter whether the target gene is expressed in the cell.Type: GrantFiled: February 27, 2013Date of Patent: January 30, 2018Assignee: Wake Forest University Health SciencesInventors: Baisong Lu, Qingguo Zhao, James Yoo, Anthony Atala
-
Patent number: 9877898Abstract: Dental material, which contains an ene compound with two or more C—C multiple bonds and a thiol according to general Formula (1) or an oligomer based on such a thiol, wherein n, p and m are chosen such that the thiol has a total of at least 3 SH groups.Type: GrantFiled: February 24, 2015Date of Patent: January 30, 2018Assignee: Ivoclar Vivadent AGInventors: Norbert Moszner, Peter Burtscher, Urs-Karl Fischer, Helmut Ritter, Monir Tabatabai, Andreas Utterodt
-
Patent number: 9862610Abstract: Methods and systems for converting a biomass and biogenic wastes to hydrogen with integrated carbon dioxide capture and storage are disclosed. In some embodiments, the methods include the following: mixing at least one of a dry solid or liquid or liquid hydroxide and catalysts with a biomass to form a biomass mixture; heating the biomass mixture until the hydroxide and the biomass react to produce hydrogen, carbonate, biochar, and potentially fertilizer; calcining the carbonate or performing double replacement reactions of the carbonate to produce sequestration-ready carbon dioxide and a hydroxide; storing the carbon dioxide produced; transferring the hydrogen produced to a fuel cell; and generating electricity with the fuel cell.Type: GrantFiled: August 7, 2012Date of Patent: January 9, 2018Assignee: The Trustees of Columbia University in the City of New YorkInventors: Ah-Hyung Alissa Park, Thomas E. Ferguson
-
Patent number: 9858664Abstract: Automated islet measurement systems (AIMS) in combination with tissue volume analysis (TVA) software effectively gauges volumetric and size-based data to generate heretofore unavailable information regarding, for example, populations of islet cells, stem cells and related desiderata.Type: GrantFiled: February 26, 2016Date of Patent: January 2, 2018Assignee: PRODO LABORATORIESInventor: Roy McCord
-
Patent number: 9850463Abstract: The production of high quality retinal pigmented epithelium (RPE) cells is necessary for research and potential therapeutic uses. Especially desirable are methods for the production of RPE cells using xeno-free culture conditions. Disclosed herein are novel methods for the production of RPE cells from pluripotent cells with high yields, including xeno-free production methods. Also provided are methods of efficiently isolating RPE cells from cultures containing heterogeneous cell types, allowing for substantially pure RPE cell cultures to be established. Additionally, novel methods for the cryopreservation of RPE cells are provided.Type: GrantFiled: January 31, 2013Date of Patent: December 26, 2017Assignee: The Regents of the University of CaliforniaInventors: Sherry Hikita, Dennis Clegg, Lincoln Johnson, Liane Miller, Marlene Tsie, Chelsea Presbrey, Lisa Conti, Michelle Maloney, David Hinton, Qirui Hu
-
Patent number: 9849183Abstract: The present disclosure herein provides a compound prescription colloidal eyedrop gel. The compound prescription colloidal eyedrop gel includes a plurality of carboxymethyl-hexanoyl chitosan (CHC) micelles, a basic structural stabilizer connecting the plurality of CHC micelles, a first drug inside the CHC micelle, and a second drug outside the CHC micelle.Type: GrantFiled: March 8, 2016Date of Patent: December 26, 2017Assignee: NATIONAL CHIAO TUNG UNIVERSITYInventors: Dean-Mo Liu, Yi-Ling Wang
-
Patent number: 9845458Abstract: Disclosed is a cell mass containing an adipose-tissue-derived multipotent progenitor cell. Also disclosed is a method for producing an adipose-tissue-derived multipotent progenitor cell from an adipose tissue, which comprises the steps of: (a) removing erythrocytes from an adipose-tissue-derived cell mass to produce a preadipose-tissue-derived multipotent progenitor cell mass; and (b) removing cells other than the adipose-tissue-derived multipotent progenitor cell from the preadipose-tissue-derived multipotent progenitor cell mass to produce the desired adipose-tissue-derived multipotent progenitor cell. Further disclosed is an adipose-tissue-derived multipotent progenitor cell produced by the method.Type: GrantFiled: June 16, 2008Date of Patent: December 19, 2017Inventors: Akifumi Matsuyama, Hiroshi Komoda, Hanayuki Ohkura, Yoshiki Sawa
-
Patent number: 9839688Abstract: A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.Type: GrantFiled: June 24, 2015Date of Patent: December 12, 2017Assignees: Provectus Pharmatech, Inc., Pfizer, Inc.Inventors: Craig J. Eagle, H. Craig Dees, Eric A. Wachter, Jamie Singer
-
Patent number: 9834604Abstract: The present invention provides a bispecific biologic comprising a ligand specific for CTLA-4 and a ligand specific for a pMHC complex.Type: GrantFiled: June 29, 2012Date of Patent: December 5, 2017Assignee: GENZYME CORPORATIONInventors: Yunxiang Zhu, Jozsef Karman, Ronnie Wei, Canwen Jiang, Seng Cheng
-
Patent number: 9833482Abstract: A pharmaceutical composition comprising as an active ingredient an isolated population of cell suspension from a mammalian fetal pulmonary tissue is disclosed. The fetal pulmonary tissue is at a developmental stage corresponding to that of a human pulmonary organ/tissue at a gestational stage selected from a range of about 20 to about 22 weeks of gestation. Methods of using the pharmaceutical composition are also disclosed.Type: GrantFiled: December 6, 2012Date of Patent: December 5, 2017Assignee: Yeda Research and Development Co. Ltd.Inventors: Yair Reisner, Elias Shezen, Chava Rosen
-
Patent number: 9829484Abstract: In one embodiment, the present invention pertains to the use of anoctamin as a biomarker for determining radiation dosimetery. In certain embodiments, the present invention relates to the use of anoctamin as a biomarker for diagnosing the presence of radiation toxicity in a subject who has been exposed to ionizing radiation, as well as for determining the absorbed radiation dose in a subject who has been exposed to a known or unknown dose of ionizing radiation. In another embodiment, the expression level of anoctamin can be used as a secondary endpoint to determine mechanisms of action and/or pharmacodynamic (PD) effects of an agent for reducing radiation toxicity.Type: GrantFiled: October 7, 2013Date of Patent: November 28, 2017Assignee: University of Florida Research Foundation, IncorporatedInventors: Sadasivan Vidyasagar, Paul Okunieff
-
Patent number: 9828634Abstract: Provided herein are systems and methods for identifying cell-specific differentiation markers. In particular, provided herein are systems and methods for generating induced pluripotent cells (IPS) from human cells, differentiating the IPS into differentiated cells, and identifying differentiation specific markers.Type: GrantFiled: January 22, 2016Date of Patent: November 28, 2017Assignee: REGENERATIVE MEDICAL SOLUTIONS, INC.Inventors: Xiaofang Xu, Jon Odorico, Erik Forsberg, Amber A. Mael, Guy Tagliavia
-
Patent number: 9827205Abstract: The invention provides a composition comprising a mixture of first microparticles that comprise fibrinogen and trehalose, and second microparticles that comprise thrombin and trehalose. The invention further provides methods for treating wounds by administering the novel microparticle composition.Type: GrantFiled: December 12, 2009Date of Patent: November 28, 2017Assignees: Mallinckrodt Pharma IP Trading D.A.C., Quadrant Drug Delivery LimitedInventors: Nicola Whitfield, Jaap Koopman, Jos Grimbergen
-
Patent number: 9827345Abstract: The methods and compositions disclosed herein are effective in the promoting the reattachment of delaminated cartilage to bone. The methods (and related compositions) comprise the removal of the acellular layer of the delaminated cartilage thereby exposing the underlying chondrocyte cells thereby allowing the promotion of the reattachment of the delaminated cartilage.Type: GrantFiled: November 8, 2013Date of Patent: November 28, 2017Assignee: Smith & Nephew, Inc.Inventors: Kelsey Jean Carvell, Ruth Cheng, Graham Smith, Drew Burdon
-
Patent number: 9828583Abstract: Provided herein are methods and compositions relating, in part, to the generation of human progenitor cells committed to the lung lineage and uses of such cells for treatment of lung diseases/disorders or injury to the lung. Whether an adult stem cell can be isolated from human adult lung remains controversial in the art and at present, methods for isolating and using adult lung stem cells from humans lack reproducibility. Thus, the methods and compositions described herein are advantageous over the present state of knowledge in the art and permit the generation of human lung progenitor cells for treatment, tissue engineering, and screening assays.Type: GrantFiled: January 11, 2013Date of Patent: November 28, 2017Assignee: THE GENERAL HOSPITAL CORPORATIONInventors: Jayaraj Rajagopal, Hongmei Mou